UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/563,024	12/30/2005	Dan Akerfeldt	030481-0251	3920
	7590 03/02/200 LARDNER LLP	EXAMINER		
SUITE 500	T NIW	BLATT, ERIC D		
3000 K STREET NW WASHINGTON, DC 20007			ART UNIT	PAPER NUMBER
			3734	
			MAIL DATE	DELIVERY MODE
			03/02/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)		
10/563,024	AKERFELDT ET AL.		
Examiner	Art Unit		
Eric Blatt	3734		

	Ene Blatt	0704
The MAILING DATE of this communication appe	ars on the cover sheet with the d	correspondence address
THE REPLY FILED <u>05 February 2009</u> FAILS TO PLACE THIS .	APPLICATION IN CONDITION FO	R ALLOWANCE.
 The reply was filed after a final rejection, but prior to or on application, applicant must timely file one of the following application in condition for allowance; (2) a Notice of Appe for Continued Examination (RCE) in compliance with 37 C periods: 	replies: (1) an amendment, affidavi eal (with appeal fee) in compliance	t, or other evidence, which places the with 37 CFR 41.31; or (3) a Request
a) The period for reply expires <u>3</u> months from the mailing date	of the final rejection.	
b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire la Examiner Note: If box 1 is checked, check either box (a) or (MONTHS OF THE FINAL REJECTION. See MPEP 706.07(the content of the co	ater than SIX MONTHS from the mailing b). ONLY CHECK BOX (b) WHEN THE	g date of the final rejection.
Extensions of time may be obtained under 37 CFR 1.136(a). The date have been filed is the date for purposes of determining the period of extunder 37 CFR 1.17(a) is calculated from: (1) the expiration date of the s set forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL	on which the petition under 37 CFR 1.1 ension and the corresponding amount of hortened statutory period for reply origi	of the fee. The appropriate extension fee nally set in the final Office action; or (2) as
 The Notice of Appeal was filed on A brief in comp filing the Notice of Appeal (37 CFR 41.37(a)), or any exter Notice of Appeal has been filed, any reply must be filed wi AMENDMENTS 	nsion thereof (37 CFR 41.37(e)), to	avoid dismissal of the appeal. Since a
3. The proposed amendment(s) filed after a final rejection, b	out prior to the date of filing a brief	will not be entered because
(a) They raise new issues that would require further cor		
(b) They raise the issue of new matter (see NOTE below	•	. – , ,
(c) They are not deemed to place the application in beti appeal; and/or	•	ducing or simplifying the issues for
(d) ☐ They present additional claims without canceling a c	corresponding number of finally reje	ected claims.
NOTE: (See 37 CFR 1.116 and 41.33(a)).		
4. The amendments are not in compliance with 37 CFR 1.12		mpliant Amendment (PTOL-324).
5. Applicant's reply has overcome the following rejection(s):6. Newly proposed or amended claim(s) would be all		timely filed amendment canceling the
non-allowable claim(s).		l be entered and an employed on at
7. For purposes of appeal, the proposed amendment(s): a) [how the new or amended claims would be rejected is prov The status of the claim(s) is (or will be) as follows: Claim(s) allowed:		r be entered and an explanation of
Claim(s) objected to:		
Claim(s) rejected:		
Claim(s) withdrawn from consideration:		
 AFFIDAVIT OR OTHER EVIDENCE The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e). 	t before or on the date of filing a No I sufficient reasons why the affidavi	otice of Appeal will <u>not</u> be entered it or other evidence is necessary and
 The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to o showing a good and sufficient reasons why it is necessary 	vercome <u>all</u> rejections under appea	al and/or appellant fails to provide a
 The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER 	n of the status of the claims after er	ntry is below or attached.
 The request for reconsideration has been considered but <u>See Continuation Sheet.</u> 	t does NOT place the application in	condition for allowance because:
12. Note the attached Information Disclosure Statement(s).	PTO/SB/08) Paper No(s)	
13. Other:	· · · · · · · · · · · · · · · ·	
/Todd E Manahan/ Supervisory Patent Examiner, Art Unit 3734		
· •		

Continuation of 11. does NOT place the application in condition for allowance because: Regarding the standing rejections over Akerfeldt in view of Kensey, Applicant argues that one skilled in the art would not incorporate teachings from Kensey into the device of Akerfeldt because the device disclosed in Kensey is used differently than the device of Akerfeldt. The Kensey reference is relied upon for its teaching that a hemostatic agent may be blended into or coated upon components used to seal a puncture in a blood vessel. Examiner maintains that this teaching is highly applicable to the device of Akerfeldt which includes components used to seal a puncture in a blood vessel. Applicant further argues that this teaching from Kensey should not be given full weight since Applicant considers it to be a "casual remakr" and Kensey states that other biologically active ingredients may be used instead of a hemostatic agent. Examiner maintains that Kensey clearly teaches uses a hemostatic agent in or on components used to seal a puncture in a blood vessel.

Regarding the standing rejections over Akerfeldt in view of Torgerson, Applicant argues that it would not have been obvious to modify the apparatus of Akerfeldt by substituting the fiber disclosed in Torgerson for the elongated member for purposes such as encouraging blood to coagulate and preventing the vessel wall from leaking since the device of Akerfeldt already seals the blood vessel and "there is nothing cited in the prior art which indicates that such an arrangement is unsatisfactory or in need of improvement." One skilled in the art would reasonably expect that replacing the elongated member of Akerfeldt with the fiber of Torgerson would decrease the likelihood of leakage through the puncture in the vessel wall in the event that the mechanical device does not perfectly seal the puncture. Thus, one skilled in the art would be motivated to make such a substitution.